Alan Kohler sits down with Paul Anderson, the CEO and managing director of Orthocell Ltd, to discuss the company's regenerative collagen platform and treatments - 9/8/24
Q: After nerves then tendons, is that the idea? Out of the same platform also our third product is for the repair of tendon, ruptured tendons or torn tendons in the body. We have submitted that now to the TGA and so we're expecting to have that approved by the end of this year or early next year. That would give us our third product from the platform and further expand our commercial opportunities leveraging up the manufacturing processes that we have in Australia and our knowledge in the marketplace. Another big unmet clinical need is in the area particularly in shoulder repair and Achilles tendon repair. Q: But how far off is that do you think? We think that's probably six to nine months before we will get the approval but bear in mind this is not the first time that the therapeutic goods administration have addressed our products. We already have two products approved in Australia and so that makes that whole process a little more simple. Certainly from a manufacturing perspective we've been able to show that it's a safe, tolerable and efficacious product.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)